Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease
Authors:
- 1 November 2007
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (11) , 1467-1472
Abstract
Introduction: Endothelin receptor antagonism has become an important component in the treatment of pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD). The purpose of this study was to analyse the safety and effectiveness of sitaxsentan, a selective antagonist of the ETA receptor, in a cohort of patients with PAH and CTD. Short-term clinical and haemodynamic effects and longer-term follow-up data are presented. Methods: A post hoc subgroup analysis was performed on 42 patients who had PAH associated with CTD, out of a group of 178 patients enrolled in a 12-week, double-blind, randomised clinical trial of sitaxsentan versus placebo. Data from 33 patients assigned to sitaxsentan 100 mg or 300 mg daily were pooled and compared with nine placebo-treated patients. There were 41 patients entered into the blinded extension study, in which all patients received either 100 mg or 300 mg sitaxsentan once daily. Results: Patients treated with sitaxsentan had a mean (SD) increase in 6 minute walk distance of 20 (5) m from baseline to week 12 (p = 0.037), whereas the placebo group had a decrease of 38 (84) m, resulting in a placebo-subtracted treatment effect of 58 m (p = 0.027). Parallel improvements in quality of life and haemodynamics were also observed. No patient discontinued their drug during the 12-week trial. In the blinded extension study (median treatment duration 26 weeks), more patients were in functional class I–II than in III–IV (pConclusions: Sitaxsentan appears to be efficacious in patients with PAH associated with CTD.Keywords
This publication has 30 references indexed in Scilit:
- Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensionsAnnals of the Rheumatic Diseases, 2006
- Clinical differences between idiopathic and scleroderma‐related pulmonary hypertensionArthritis & Rheumatism, 2006
- Systemic sclerosis associated pulmonary hypertension: improved survival in the current eraHeart, 2006
- Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist SitaxsentanJACC, 2006
- Long-Term Outcome of Bosentan Treatment in Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated with the Scleroderma Spectrum of DiseasesThe Journal of Heart and Lung Transplantation, 2005
- The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community‐based rheumatologists (the UNCOVER study)Arthritis & Rheumatism, 2005
- Survival with first-line bosentan in patients with primary pulmonary hypertensionEuropean Respiratory Journal, 2005
- A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonismAnnals of the Rheumatic Diseases, 2004
- Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachAnnals of the Rheumatic Diseases, 2003
- Survival in Primary Pulmonary HypertensionCirculation, 2002